中华心脏与心律电子杂志 ›› 2018, Vol. 06 ›› Issue (01) : 52 -54. doi: 10.3877/cma.j.issn.2095-6568.2018.01.018 × 扫一扫
所属专题： 文献；
论著
收稿日期:
出版日期:
Yuanlin Luo1, Yanmei Xu2, Linling Li1, Jinlong Yang1
Received:
Published:
罗远林, 徐燕梅, 李林玲, 杨锦龙. 比索洛尔联合低分子肝素治疗不稳定型心绞痛的效果分析[J]. 中华心脏与心律电子杂志, 2018, 06(01): 52-54.
Yuanlin Luo, Yanmei Xu, Linling Li, Jinlong Yang. Efficacy and safety of bisoprolol combined with low molecular heparin in the treatment of unstable angina pectoris[J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2018, 06(01): 52-54.
探讨比索洛尔联合低分子肝素治疗不稳定型心绞痛的临床效果。
将89例不稳定型心绞痛患者按随机数表法分为两组，A组(44例)接受比索洛尔辅助治疗，B组(45例)在A组治疗基础上接受低分子肝素辅助治疗。统计两组患者治疗总有效率及不良反应发生率，检测两组患者治疗前后血液流变学指标水平和心功能指标水平。
A组治疗总有效率(81.82%)低于B组(95.56%)，P<0.05；两组患者不良反应发生率差异无统计学意义(P>0.05)；治疗后B组患者血液流变学指标水平均低于A组(P<0.05)；治疗后B组患者LVESD、LVEDD水平均低于A组，但LVEF水平较高。
比索洛尔联合低分子肝素治疗可有效改善不稳定型心绞痛患者凝血状态和心功能，且不会增加用药风险，可在临床推广。
To observe the efficacy and safety of bisoprolol combined with low molecular weight heparin in the treatment of unstable angina pectoris.
Eighty-nine patients with unstable angina pectoris were randomly divided into two groups (A=44, B=45). Group A was treated with bisoprolol on the basis of routine treatment, and group B was treated with low molecular weight heparin on the basis of group A. The total effective rate and the incidence of adverse reactions were counted, and the levels of hemorheology and cardiac function were measured before and after treatment.
The total effective rate (81.82%) in group A was lower than that in group B (95.56%) and P<0.05. There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The hemorheological indexes in group B were lower than those in group A (P<0.05). The levels of LVESD and LVEDD in group B were lower than those in group A after treatment, but the levels of LVEF were higher.
Bisoprolol combined with low molecular weight heparin can effectively improve coagulation status and cardiac function in patients with unstable angina pectoris, and does not increase the risk of drug use, which can be promoted in clinical practice.